nimacimab glp-1 news Amycretin — a novel obesity treatment that targets both and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD Skye Bioscience Q2 2025 slides:

S3), thus showing that cleavage was due to DPP-4

The most commonly prescribed GLP-1 agonist is semaglutide, which has gained popularity in recent years after the Food and Drug Administration (FDA) approved it for the treatment of diabetes in 2017 (under the brand name Ozempic), for the treatment of obesity in 2021 (under the brand name Wegovy), and for reducing cardiovascular disease risk in 2024 (Wegovy)

Smoking status and life expectancy after acute myocardial infarction in the elderly

The data were released through a Lilly press announcement on May 21, 2026

Individual results are never guaranteed, and regulatory guidance in this area continues to evolve our clinical offerings follow it